Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over […]
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over […]
Columbia Sportswear reported declining performance in Q3 2024, with net sales decreasing 5% to $931.8
– Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million – – GAAP Diluted EPS
CARLSBAD, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),
Pharming Group N.V. Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023,
argenx SE October 24, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to
Garrett Motion (GTX) reported Q3 2024 financial results with net sales of $826 million, down
Tractor Supply Company (NASDAQ: TSCO) reported Q3 2024 financial results with net sales increasing 1.6%